The AZD3759 cohort of the BLOOM trial evaluated the safety, tolerability, and early efficacy of AZD3759 in 29 patients with advanced EGFR mutation-positive NSCLC and metastases, including LM (27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.